{"filing":{"accession_number":"0001829126-26-010385","cik":"0002000775","ticker":"BKHAU","company_name":"Black Hawk Acquisition Corp","form":"8-K","filing_date":"2026-09-24","report_date":"2026-09-22","primary_document":"blackhawkacq_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2000775/000182912626010385/blackhawkacq_8k.htm"},"events":[{"id":34893,"run_id":32128,"accession_number":"0001829126-26-010385","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"Black Hawk Acquisition Corp entered into material financing and related agreements (Forward Purchase Agreement, Non-Redemption Agreement, Subscription Agreement, Standby Equity Purchase Agreement, and Registration Rights Agreement) with Meteora in connection with its previously announced business combination with Vesicor Therapeutics, including equity purchase commitments up to $200 million and share forward transactions.","company_name":"Black Hawk Acquisition Corp","ticker":"BKHAU","filing_date":"2026-09-24","form":"8-K","submitted_at":null,"items":[{"id":38757,"accession_number":"0001829126-26-010385","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Black Hawk Acquisition Corp entered into a series of material financing and related agreements (Forward Purchase Agreement, Non-Redemption Agreement, Subscription Agreement, Standby Equity Purchase Agreement, and Registration Rights Agreement) with Meteora in connection with its previously announced business combination with Vesicor Therapeutics. The filing explicitly states these agreements are \"in connection with the Company's previously announced business combination with Vesicor\" and describes the domestication and name change to Vesicor Therapeutics Holdings, Inc. as PubCo. While the business combination agreement itself was dated April 26, 2025, this 8-K discloses material financing arrangements entered into on September 22, 2026 that are integral to the business combination transaction structure, including equity purchase commitments up to $200 million and share forward transactions. This constitutes material M\u0026A-related activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T20:17:19.264979+00:00","company_name":"","ticker":null,"filing_date":""},{"id":38758,"accession_number":"0001829126-26-010385","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses unregistered sales of equity securities under Section 4(a)(2) of the Securities Act. The filing describes issuance of PubCo common stock pursuant to a Subscription Agreement and SEPA, including shares issuable upon conversion of convertible promissory notes and commitment fee shares. This is a classic dilutive private placement structure typical of SPAC transactions, material to investors assessing ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T20:17:19.264979+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38757,"accession_number":"0001829126-26-010385","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Black Hawk Acquisition Corp entered into a series of material financing and related agreements (Forward Purchase Agreement, Non-Redemption Agreement, Subscription Agreement, Standby Equity Purchase Agreement, and Registration Rights Agreement) with Meteora in connection with its previously announced business combination with Vesicor Therapeutics. The filing explicitly states these agreements are \"in connection with the Company's previously announced business combination with Vesicor\" and describes the domestication and name change to Vesicor Therapeutics Holdings, Inc. as PubCo. While the business combination agreement itself was dated April 26, 2025, this 8-K discloses material financing arrangements entered into on September 22, 2026 that are integral to the business combination transaction structure, including equity purchase commitments up to $200 million and share forward transactions. This constitutes material M\u0026A-related activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T20:17:19.264979+00:00","company_name":"Black Hawk Acquisition Corp","ticker":"BKHAU","filing_date":"2026-09-24"},{"id":38758,"accession_number":"0001829126-26-010385","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses unregistered sales of equity securities under Section 4(a)(2) of the Securities Act. The filing describes issuance of PubCo common stock pursuant to a Subscription Agreement and SEPA, including shares issuable upon conversion of convertible promissory notes and commitment fee shares. This is a classic dilutive private placement structure typical of SPAC transactions, material to investors assessing ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T20:17:19.264979+00:00","company_name":"Black Hawk Acquisition Corp","ticker":"BKHAU","filing_date":"2026-09-24"}]}